Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 10/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.35 |
| ▸ | MLYCD | O95822 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17345781 | 0.78 | ESR1 (0.39) | NR1H3NR1H2MLYCDHSD11B1NR1I2 | |
| SCHEMBL17342250 | 0.73 | ALDH1A1 (0.44) | — | |
| SCHEMBL17342247 | 0.73 | LTA4H (0.39) | NR1H2 | |
| SCHEMBL2574194 | 0.71 | MEN1 (0.42) | OPRM1OPRL1 | |
| SCHEMBL5079313 | 0.69 | ALDH1A1 (0.52) | NR1H3NR1H2HSD11B1 | |
| SCHEMBL16755617 | 0.69 | TDP1 (0.43) | — | |
| SCHEMBL20025824 | 0.68 | CYP2C19 (0.44) | — | |
| SCHEMBL20021864 | 0.68 | TSHR (0.46) | OPRM1OPRL1 | |
| SCHEMBL11725710 | 0.67 | TSHR (0.40) | — | |
| SCHEMBL11729000 | 0.67 | APP (0.39) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562062-B2 | Ligand compound, organic chromium compound, catalyst system for ethylene oligomerization, and method for ethylene oligomerization using the same | LG CHEM, LTD (KR) | 2017-02-07 | — | — | US | disclosed |
| US-20150361118-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLEFIN OLIGOMERIZATION USING THE SAME | LG CHEM, LTD. (KR) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361118-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLEFIN OLIGOMERIZATION USING THE SAME | OXER1, OSTC, OR51E2 | NR1H3 213/4885NR1H2 306/4885MLYCD 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.